U.S. Gastric Cancer Diagnostics Market Size, Share, Trends, Industry Analysis Report: By Product (Reagents & Consumables, Instruments), By Disease Type, By End Use

Description

List of Tables

The U.S. gastric cancer diagnostics market size is expected to reach USD 935.48 million by 2034, according to a new study by Polaris Market Research. The report "U.S. Gastric Cancer Diagnostics Market Size, Share, Trends, Industry Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type, By End Use - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The U.S. gastric cancer diagnostics market focuses on all the medical procedures, tests, and tools used to find and confirm stomach cancer. This involves everything from initial screenings and imaging to more detailed lab tests such as biopsies and molecular analysis. The primary goal of these diagnostics is to detect the disease early, understand disease progression, and assist doctors in determining the most effective treatment plan for each patient.

The U.S. gastric cancer diagnostics market growth is driven by the rising awareness about the importance of early cancer diagnosis. Early cancer detection encourages more people to get screened and seek diagnostic testing. Rising technological advancements in medical are also playing a big role, leading to more accurate and less invasive diagnostic methods. Additionally, owing to the increasing focus on personalized medicine, more detailed diagnostic information is needed to create tailored treatment plans for individual patients. These elements combined create a strong demand for sophisticated gastric cancer diagnostic solutions.

U.S. Gastric Cancer Diagnostics Market Report Highlights:

By product, the reagents & consumables segment held a larger share of the U.S. gastric cancer diagnostics industry in 2024, driven by the constant need for these materials in everyday diagnostic procedures.

By disease type, the adenocarcinoma segment held the largest share in 2024, accounting for the vast majority of stomach cancer diagnoses. Due to its high prevalence, diagnostic efforts and research are primarily focused on developing and utilizing tools specific to this form of cancer.

By end use, hospitals held the largest share in 2024. Hospitals serve as the primary point of care for initial patient contact and offer a full spectrum of diagnostic services. Their integrated approach, providing everything from imaging to pathology under one roof, makes them central to the diagnostic process nationwide.

A few key players in the market include Abbott Laboratories; Becton, Dickinson and Company (BD); Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Agilent Technologies, Inc.; Illumina, Inc.; QIAGEN N.V.; Exact Sciences Corporation; Mirxes Pte Ltd; and GE HealthCare.

Polaris Market Research has segmented the U.S. gastric cancer diagnostics market report on the basis of product, disease type, and end use:

By Product Outlook (Revenue - USD Million, 2020-2034)

Reagents & Consumables

Instruments

By Disease Type Outlook (Revenue - USD Million, 2020-2034)

Adenocarcinoma

Gastric lymphoma

Others

By End Use Outlook (Revenue - USD Million, 2020-2034)

Hospitals

Diagnostic Laboratories

Diagnostic Imaging

Product Code: PM5916

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. U.S. Gastric Cancer Diagnostics Market Insights

4.1. U.S. Gastric Cancer Diagnostics Market - Market Snapshot
4.2. U.S. Gastric Cancer Diagnostics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Emphasis on Early Detection and Screening Programs
  - 4.2.1.2. Advancements in Diagnostic Technologies
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Lack of standardized screening guidelines
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. U.S. Gastric Cancer Diagnostics Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. U.S. Gastric Cancer Diagnostics Market, by Product

5.1. Key Findings
5.2. Introduction
- 5.2.1. U.S. Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Million)
5.3. Reagents & Consumables
- 5.3.1. U.S. Gastric Cancer Diagnostics Market, by Reagents & Consumables, by Region, 2020-2034 (USD Million)
5.4. Instruments
- 5.4.1. U.S. Gastric Cancer Diagnostics Market, by Instruments, by Region, 2020-2034 (USD Million)

6. U.S. Gastric Cancer Diagnostics Market, by Disease Type

6.1. Key Findings
6.2. Introduction
- 6.2.1. U.S. Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Million)
6.3. Adenocarcinoma
- 6.3.1. U.S. Gastric Cancer Diagnostics Market, by Adenocarcinoma, by Region, 2020-2034 (USD Million)
6.4. Gastric lymphoma
- 6.4.1. U.S. Gastric Cancer Diagnostics Market, by Gastric lymphoma, by Region, 2020-2034 (USD Million)
6.5. Others
- 6.5.1. U.S. Gastric Cancer Diagnostics Market, by Others, by Region, 2020-2034 (USD Million)

7. U.S. Gastric Cancer Diagnostics Market, by End Use

7.1. Key Findings
7.2. Introduction
- 7.2.1. U.S. Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Million)
7.3. Hospitals
- 7.3.1. U.S. Gastric Cancer Diagnostics Market, by Others, by Region, 2020-2034 (USD Million)
7.4. Diagnostic Laboratories
- 7.4.1. U.S. Gastric Cancer Diagnostics Market, by Others, by Region, 2020-2034 (USD Million)
7.5. Diagnostic Imaging
- 7.5.1. U.S. Gastric Cancer Diagnostics Market, by Others, by Region, 2020-2034 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Abbott Laboratories
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Agilent Technologies, Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Becton, Dickinson and Company (BD)
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Bio-Rad Laboratories, Inc.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Exact Sciences Corporation
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. F. Hoffmann-La Roche Ltd.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. GE HealthCare
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Illumina, Inc.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Mirxes Pte Ltd
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. QIAGEN N.V.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
9.11. Thermo Fisher Scientific Inc.
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development